See more : MetaReal Corporation (6182.T) Income Statement Analysis – Financial Results
Complete financial analysis of Biodexa Pharmaceuticals Plc (BDRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodexa Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Blue Safari Group Acquisition Corp. (BSGAU) Income Statement Analysis – Financial Results
- BR Malls Participações S.A. (BRMSY) Income Statement Analysis – Financial Results
- Hsing Ta Cement Co., Ltd. (1109.TW) Income Statement Analysis – Financial Results
- Nofoth Food Products Company (9556.SR) Income Statement Analysis – Financial Results
- PT Bukit Darmo Property Tbk (BKDP.JK) Income Statement Analysis – Financial Results
Biodexa Pharmaceuticals Plc (BDRX)
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 381.00K | 699.00K | 578.00K | 343.00K | 674.00K | 1.94M | 989.00K | 1.32M | 1.38M | 157.00K | 147.00K | 0.00 |
| Cost of Revenue | 4.07M | 5.11M | 4.65M | 6.07M | 7.84M | 9.36M | 8.33M | 7.73M | 70.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.69M | -4.41M | -4.08M | -5.73M | -7.17M | -7.42M | -7.34M | -6.41M | 1.31M | 157.00K | 147.00K | 0.00 |
| Gross Profit Ratio | -967.45% | -631.19% | -705.19% | -1,669.10% | -1,063.65% | -382.92% | -742.16% | -484.28% | 94.91% | 100.00% | 100.00% | 0.00% |
| Research & Development | 4.07M | 5.11M | 4.65M | 16.15M | 7.84M | 9.36M | 9.83M | 7.73M | 8.71M | 5.44M | 2.84M | 1.65M |
| General & Administrative | 4.34M | 4.54M | 2.95M | 4.96M | 3.84M | 4.39M | 4.27M | 3.25M | 2.08M | 4.23M | 1.81M | 2.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 6.00K | 323.00K | 0.00 | 170.00K | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.34M | 4.54M | 2.95M | 4.96M | 4.16M | 4.39M | 4.44M | 3.25M | 2.69M | 4.23M | 1.81M | 2.36M |
| Other Expenses | -4.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.33M | 4.05M | 1.99M | 17.71M | 3.67M | 4.39M | 5.54M | 2.07M | 12.59M | 9.84M | 4.65M | 4.01M |
| Cost & Expenses | 8.40M | 9.16M | 6.64M | 23.78M | 11.51M | 13.75M | 13.87M | 9.80M | 12.66M | 9.84M | 4.65M | 4.01M |
| Interest Income | 83.00K | 24.00K | 44.00K | 33.00K | 89.00K | 585.00K | 94.00K | 91.00K | 48.00K | 153.00K | 384.00K | 557.00K |
| Interest Expense | 41.00K | 53.00K | 44.00K | 34.00K | 97.00K | 587.00K | 109.00K | 0.00 | 0.00 | 161.00K | 248.00K | 0.00 |
| Depreciation & Amortization | 283.00K | 343.00K | 403.00K | 1.22M | 1.29M | 1.11M | 1.17M | 4.35M | 736.00K | 321.00K | 246.00K | 194.00K |
| EBITDA | -7.16M | -7.40M | -5.66M | -22.22M | -9.54M | -10.70M | -10.61M | -5.30M | -10.49M | -9.36M | -4.25M | -3.81M |
| EBITDA Ratio | -1,879.53% | -1,252.50% | -1,173.88% | -2,790.67% | -1,533.53% | -552.32% | -1,072.70% | -400.76% | -680.44% | -4,709.55% | -2,893.20% | 0.00% |
| Operating Income | -8.01M | -8.93M | -7.00M | -10.67M | -11.32M | -11.82M | -11.78M | -9.65M | -10.09M | -7.72M | -4.50M | -4.01M |
| Operating Income Ratio | -2,103.41% | -1,277.83% | -1,210.73% | -3,111.08% | -1,679.23% | -609.65% | -1,190.70% | -729.55% | -733.96% | -4,914.01% | -3,060.54% | 0.00% |
| Total Other Income/Expenses | 529.00K | 444.00K | 892.00K | -430.00K | 395.00K | -585.00K | -1.19M | 1.26M | 1.69M | -153.00K | -384.00K | -557.00K |
| Income Before Tax | -7.49M | -8.49M | -6.11M | -23.47M | -10.92M | -12.40M | -12.97M | -8.39M | -11.23M | -9.84M | -4.88M | -4.57M |
| Income Before Tax Ratio | -1,964.57% | -1,214.31% | -1,056.40% | -6,842.57% | -1,620.62% | -639.83% | -1,311.43% | -634.01% | -816.87% | -6,267.52% | -3,321.77% | 0.00% |
| Income Tax Expense | -406.00K | 832.00K | 646.00K | 1.28M | 1.79M | 2.03M | 1.27M | 2.23M | 1.13M | 1.02M | 799.00K | 571.00K |
| Net Income | -7.08M | -7.66M | -5.46M | -22.19M | -9.14M | -10.37M | -11.71M | -6.16M | -10.10M | -8.82M | -4.08M | -3.99M |
| Net Income Ratio | -1,858.01% | -1,095.28% | -944.64% | -6,469.10% | -1,355.79% | -534.98% | -1,183.52% | -465.68% | -734.47% | -5,619.11% | -2,778.23% | 0.00% |
| EPS | -224.13 | -619.72 | -542.31 | -4.14K | -3.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -224.13 | -619.72 | -542.31 | -4.14K | -3.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 31.59K | 12.35K | 10.07K | 5.36K | 2.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 31.59K | 12.35K | 10.07K | 5.36K | 2.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
Orally dosed small molecule candidate is designed to reduce/eliminate need for injectable insulin Topline data from Phase 2a program expected by year-end Safety profile established in more than 700 patients CARDIFF, UK / ACCESSWIRE / March 1, 2024 / While...
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival of 16.5 Months vs 10.0 months in Comparable Cohort CARDIFF, United Kingdom,...
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
Biodexa Pharmaceuticals PLC Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing...
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024 CARDIFF, United Kingdom, Jan. 22, 2024 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company...
Biodexa Appoints Ann Merchant to the Board of Directors
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative...
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of exclusive, worldwide license to Tolimidone, Phase II Ready Type I Diabetes clinical program CARDIFF, United...
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) CARDIFF, United Kingdom, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical...
Biodexa (BDRX) gained 91% in a single day: should you buy?
Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) is trending after favourable stock market news. The stock gained 91% in a single day and is up more than 107% in the last five days.
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes Highlights: Acquisition...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary...
Source: https://incomestatements.info
Category: Stock Reports